ARMI | BioFabUSA seeks to make practical the large-scale manufacturing of engineered tissues and tissue-related technologies. To carry out this mission, ARMI | BioFabUSA held a Technical Project Call that specifically sought solutions for the automation and monitoring of engineered tissues. Automation is essential for enabling consistency, scale, and post-delivery assurance for tissue identity, viability, function and efficacy. Advanced Solutions Life Sciences (ASLS), in partnership with GE Healthcare Life Sciences (GE HLS), responded to this call and their project submission was awarded.
Their project, titled “Generalized Biomanufacturing Platform for Dynamic Vascularized Tissues,” proposes the development of a manufacturing workflow solution for the building of vascularized tissue that is suitable for use in clinical applications and non-clinical commercial spaces. The technical approach of this project involves the development and integration of task-specific controls within existing equipment, in combination with new manufacturing tool sets and microfluidic capabilities, to create a vascularized tissue.
Renowned for their 6-axis robotic bioprinter/biofabricator, also known as the BioAssemblyBot® (BAB), ASLS has partnered with GE HLS to combine their respective technologies to advance the capabilities of the BAB to include multiple automated workflow capabilities, elevating tissue fabrication from a laboratory phenomena into a manufacturing process. Jay Hoying, Partner and Chief Scientist at ASLS and Project Lead, states “The motivation for the project really speaks to the broader mission that we had at ASLS for tissue manufacturing, which ARMI helped to crystallize. The Bio-Assembly® platform that we currently have, while it does tissue printing, was envisioned to be an automated tissue engineering platform.”
For more information on each of these projects and to read about them in greater detail, visit our Community Portal Page! This benefit is available exclusively to members of the ARMI | BioFabUSA Community.